NCT03143933

Brief Summary

It is hypothesized that propofol, when used in general anesthesia (GA) influence patient's stress status and consequently affect stress response parameters. Hence, the objective of the presented research is to assess whether the propofol has anti-stress effect or not in patients undergoing surgeries that require GA and classified as The American Society of Anesthesiologists physical status 1 (ASA PS1)

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jul 2016

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2016

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

April 22, 2017

Completed
16 days until next milestone

First Posted

Study publicly available on registry

May 8, 2017

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2017

Completed
Last Updated

May 8, 2017

Status Verified

May 1, 2017

Enrollment Period

1 year

First QC Date

April 22, 2017

Last Update Submit

May 4, 2017

Conditions

Keywords

propofol, BIS, general anesthesia

Outcome Measures

Primary Outcomes (1)

  • Primary end point; assessment of change in blood biochemical indicators of surgical stress

    blood testing includes: Catecholamines 1. Epinephrine 2. Nor epinephrine , Fasting blood glucose, Insulin level, Cortisol, Vasopressin, and Cytokines

    blood sample will withdrawn before induction of anesthesia with 10 mins and after induction of anesthesia with 3 mins

Secondary Outcomes (3)

  • Secondary end point; assessment of change in BIS number

    BIS readings will be recorded before induction of anesthesia with 10 mins and after induction of anesthesia with 3 mins

  • Tertiary end point; assessment of change in blood pressure

    blood pressure readings will be recorded before induction of anesthesia with 10 mins and after induction of anesthesia with 3 mins

  • Quaternary end point; assessment of change in heart rate

    heart rate readings will be recorded before induction of anesthesia with 10 mins and after induction of anesthesia with 3 mins

Study Arms (2)

propofol

ACTIVE COMPARATOR

this arm will receive propofol in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins

Drug: Propofol

propofol and fentanyl

ACTIVE COMPARATOR

this arm will receive propofol and fentanyl in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins

Drug: PropofolDrug: Fentanyl

Interventions

I.V propofol

propofolpropofol and fentanyl
Also known as: propofol
propofol and fentanyl

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA1

You may not qualify if:

  • Patients who refused to participate in the study or to sign the consent form
  • The very young and very old patients
  • Severely agitated (panicked).
  • ASA1 patients who had bradycardia during propofol induction and was reversed with atropine.
  • Patients with any of the following pathologies: liver, kidney, lung, or cardiac diseases, allergic to medicines, alcohol abuse, pregnant, or having endocrine or neuropsychiatric diseases. Moreover, those with sepsis syndrome with hemodynamic instability, hypothermia, and poorly controlled coagulopathy will not be enrolled in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kasr Al Aini

Cairo, Egypt

RECRUITING

MeSH Terms

Interventions

PropofolFentanyl

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Teaching assistant

Study Record Dates

First Submitted

April 22, 2017

First Posted

May 8, 2017

Study Start

July 1, 2016

Primary Completion

July 1, 2017

Study Completion

September 1, 2017

Last Updated

May 8, 2017

Record last verified: 2017-05

Locations